Trade ATRA anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Atara Biotherapeutics, Inc. (ATRA) is trading at US$9.20, down 0.54% today as of Aug 28, 16:00 EDT. The company has a market capitalisation of US$97.37M. Over the past 52 weeks, ATRA has traded between US$3.92 and US$19.15. On Syfe you can trade ATRA with $0 commission and add it to your watchlist.
| Previous close | US$9.25 |
|---|---|
| Market cap | US$97.37M |
| P/E ratio | 452.49 |
| 52-week range | US$3.92 – US$19.15 |
| Volume | 15.34K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.
Year: 2014
--Canaccord Genuity Upgrades Atara Biotherapeutics to Buy From Hold, Adjusts Price Target to $13 From $6
May 8, 11:22 AM · MT Newswires
Atara Biotherapeutics, Inc. (ATRA) stock is trading at US$9.20, -0.54% from the previous close of US$9.25.
The market cap for Atara Biotherapeutics, Inc. (ATRA) stock is approximately US$97.37M.
The price-to-earnings ratio for Atara Biotherapeutics, Inc. (ATRA) is 452.49, based on the latest reported earnings.
The 52-week high for Atara Biotherapeutics, Inc. (ATRA) stock is US$19.15.
The 52-week low for Atara Biotherapeutics, Inc. (ATRA) stock is US$3.92.
Atara Biotherapeutics, Inc. (ATRA) does not currently pay a dividend.
Stay on top of ATRA
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
